Urethra and Bladder Dosimetry in Patients Treated with Prostate SBRT with and without Intra-Prostatic Boost (IPB)
Nisha Bhargava et al. | ASTRO 2024
Early PSA Kinetics in Patients Treated with Prostate SBRT with Intra-Prostatic Boost
Nima Aghdam et al. | ASTRO 2024
Early Results from a Prospective Trial Testing Stereotactic Salvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy-STARR (NCT05455736)
Giulio Francolini et al. | ASTRO 2024
Urinary Quality of Life in Patients Treated with Prostate SBRT with Intra-Prostatic Boost
Nisha Bhargava et al. | ASTRO 2024
Moderately Hypofractionated Helical TomoTherapy for Prostate Cancer: Ten-year Experience of a Mono-institutional Series of 415 Patients
Cozzi S, Ruggieri MP, Alì E, Ghersi SF, Vigo F, Augugliaro M, Giaccherini L, Iori F, Najafi M, Bardoscia L, Botti A, Trojani V, Ciammella P, Iotti C | In Vivo | 2023
Salvage Stereotactic Reirradiation for Intraprostatic Cancer Recurrence: A Large Retrospective Study
Allali S, Loap P, Bibault JE, Krepps S, Deforge A, Moreau D, Durdux C, Giraud P | Prostate | 2023
Large Prostate Volume Does Not Negatively Impact Health-Related Quality of Life in Patients with Prostate Cancer Treated with Ultra-hypofractionated Stereotactic Body Radiotherapy
Piotr Milecki, Anna Adamska, Anna Rucinska, Grzegorz Pałucki, Agnieszka Szumiło, Agnieszka Skrobała, Agata Jodda, Michał Michalak | J Pers Med | 2023
Stereotactic Body Radiation Therapy for Prostate Cancer: A Study Comparing 3-year Genitourinary Toxicity Between CyberKnife and Volumetric-Modulated Arc Therapy by Propensity Score Analysis
Makoto Ito, Yasuo Yoshioka, Yuuki Takase, Junji Suzuki, Hironori Takahashi, Yoshitaka Minami, Ami Sakuragi, Yukihiko Oshima, Takahito Okuda, Kojiro Suzuki | Radiat Oncol | 2023
Robotic Stereotactic Body Radiotherapy for Localized Prostate Cancer: Final Analysis of the German Hypostat Trial
David Krug, Detlef Imhoff, Alfred Haidenberger, Nicole Heßler, Jane Schäfer, Stefan Huttenlocher, Georgios Chatzikonstantinou, Christoph Fürweger, Ulla Ramm, Inke R König, Felix Chun, Michael Staehler, Claus Rödel, Alexander Muacevic, Reinhard Vonthein, Jürgen Dunst, Oliver Blanck | Strahlenther Onkol | 2023
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall […]
High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes
Tomita N, Soga N, Ogura Y, Hayashi N, Kageyama T, Ito M, Koide Y, Yoshida M, Kimura K, Makita C, Tachibana H, Kodaira T | J Cancer Res Clin Oncol | 2016
Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study
Di Muzio NG, Fodor A, Noris Chiorda B, Broggi S, Mangili P, Valdagni R, Dell’Oca I, Pasetti M, Deantoni CL, Chiara A, Berardi G, Briganti A, Calandrino R, Cozzarini C, Fiorino C | Clin Oncol | 2016
High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer
Yamazaki H, Masui K, Suzuki G, Nakamura S, Shimizu D, Nishikawa T, Okabe H, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K | Cancers (Basel) | 2018
Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost for Clinically Node-Positive Prostate Cancer: A Single-Institutional Retrospective Study
Onishi M, Kawamura H, Murata K, Inoue T, Murata H, Takakusagi Y, Okonogi N, Ohkubo Y, Okamoto M, Kaminuma T, Sekihara T, Nakano T, Ohno T | Cancers (Basel) | 2021
Post-operative hypofractionated radiotherapy for prostate cancer: a mono-institutional analysis of toxicity and clinical outcomes
Ferrera G, D’Alessandro S, Cuccia F, Serretta V, Trapani G, Savoca G, Mortellaro G, Lo Casto A | J Cancer Res Clin Oncol | 2022
Moderate Hypofractionated Helical TomoTherapy for Older Patients with Localized Prostate Cancer: Long-term Outcomes of a Phase I-II Trial
Cui D, Du L, Yu W, Cai B, Meng L, Yang J, Luo Y, Chen J, and Ma L | Radiol Oncol| 2022
Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial
Macias VA, Barrera-Mellado I | BJU Int | 2020
Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints
Meier RM, Bloch DA, Cotrutz C, Beckman AC, Henning GT, Woodhouse SA, Williamson SK, Mohideen N, Dombrowski JJ, Hong RL, Brachman DG, Linson PW, Kaplan ID. | Int J Radiat Oncol Biol Phys | 2018
Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial
Wang K, Chen RC, Kane B, Medbery CA, Underhill K, Gray JR, Peddada AV, Fuller DB | Int J Radiat Oncol Biol Phys | 2018
5-year Biochemical Outcomes of Stereotactic Body Radiotherapy with Intraprostatic Dose Escalation for Unfavorable Prostate Cancer
Blacksburg SR, Aghdam N, Royce TJ, Burri RJ, Obayomi-Davies O, Mezeckis M, Meier R, Fuller DB, Chen RC, Lanciano RM, Haas JA, Collins SP | Int J Radiat Oncol Biol Phys | 2019
